Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer

1 May 2019

Abstract excerpt

BRAF V600E mutations occur in approximately 40% of all patients with papillary thyroid cancer (PTC) and are associated with a worse prognosis in population studies. Treatment with single-agent BRAF inhibitors can result in nondurable partial responses (PRs) in clinical trials, but resistance inevitably develops. The mechanisms of resistance are not completely understood, but in non-thyroid tumors harboring BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Melanoma and MAPK Pathways
Share to S100 Proteins and Annexins
Share to Thyroid Cancer Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31085763
DOI: 10.6004/jnccn.2019.7292

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid CancerPMID 31085763Read ↗

Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors.Semantic proximity Read ↗

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.Semantic proximity Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma modelSemantic proximity Read ↗

Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics.Semantic proximity Read ↗

Role of BRAF in thyroid oncogenesis.Semantic proximity Read ↗

Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.Semantic proximity Read ↗

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.Semantic proximity Read ↗

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.Semantic proximity Read ↗

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.Semantic proximity Read ↗

Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.Semantic proximity Read ↗

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.